
Gilead Sciences recently excluded Malaysia, as well as Singapore and Brunei, from obtaining generic versions of remdesivir -- the frontrunner potential treatment for Covid-19 – in recent deals the US pharmaceutical giant struck with five generic companies in India and Pakistan.